Dimerix Advances DMX-200 in Kidney Disease Trial

Dimerix Limited (AU:DXB) has released an update.

Dimerix Limited has announced the progression of its first patient from the successful ACTION3 Phase 3 clinical trial into a two-year open-label extension study for the kidney disease treatment, DMX-200. This extension will enable the collection of long-term data on the drug’s safety and efficacy, which is crucial for future regulatory submissions. The study is significant for patients with focal segmental glomerulosclerosis (FSGS), offering continuous access to DMX-200 and contributing valuable insights into its long-term therapeutic potential.

For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.